Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women

LG Bekker, M Das, Q Abdool Karim… - … England Journal of …, 2024 - Mass Medical Soc
Background There are gaps in uptake of, adherence to, and persistence in the use of
preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among …

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

UM Parikh, JW Mellors - Current opinion in HIV and AIDS, 2016 - journals.lww.com
The benefit of preventing HIV-1 infections with TDF/FTC PrEP far outweighs the risk of drug-
resistant infection, provided PrEP is not started in persons with undiagnosed HIV-1 infection …

Cabotegravir long-acting for HIV-1 prevention

CD Andrews, W Heneine - Current Opinion in HIV and AIDS, 2015 - journals.lww.com
PrEP, after approval of Truvada, continues to evolve to address adherence limitations of
daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits …

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

CD Andrews, YL Yueh, WR Spreen… - Science translational …, 2015 - science.org
Long-acting GSK1265744 (GSK744 LA) is a strand transfer inhibitor of the HIV/SIV (simian
immunodeficiency virus) integrase and was shown to be an effective preexposure …

Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis

CYX Chua, P Jain, A Ballerini, G Bruno… - Journal of controlled …, 2018 - Elsevier
Pre-exposure prophylaxis (PrEP) with antiretroviral (ARV) drugs are effective at preventing
human immunodeficiency virus (HIV) transmission. However, implementation of PrEP …

Safety and pharmacokinetics of a tenofovir alafenamide fumarate-emtricitabine based oral antiretroviral regimen for prevention of HIV acquisition in women: a …

AR Thurman, JL Schwartz, ML Cottrell, V Brache… - …, 2021 - thelancet.com
Background Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF)
combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women …

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

JM Smith, R Rastogi, RS Teller… - Proceedings of the …, 2013 - National Acad Sciences
Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal
exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase …

Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates

FP Pons-Faudoa, N Di Trani, S Capuani… - Science translational …, 2023 - science.org
The impact of pre-exposure prophylaxis (PrEP) on slowing the global HIV epidemic hinges
on effective drugs and delivery platforms. Oral drug regimens are the pillar of HIV PrEP, but …

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

T Whitfield, A Torkington… - HIV/AIDS-Research and …, 2016 - Taylor & Francis
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis
(PrEP) and treatment of HIV infection. There is a demand for prevention and treatment …

Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues

I Massud, W Aung, A Martin, S Bachman… - Journal of …, 2013 - Am Soc Microbiol
Maraviroc (MVC) is a potent CCR5 coreceptor antagonist that is in clinical testing for daily
oral pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model …